News

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved ...
Vifor International AG (CSL Vifor): CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI in IgA Nephropathy
European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation ...